Takeda Pharmaceutical Co Ltd ADR Cash Flow Conversion Efficiency
Takeda Pharmaceutical Co Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) has a cash flow conversion efficiency ratio of 0.047x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($360.04 Billion) by net assets ($7.65 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Takeda Pharmaceutical Co Ltd ADR market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Takeda Pharmaceutical Co Ltd ADR (2001–2025)
Cash flow conversion efficiency of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025. This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Takeda Pharmaceutical Co Ltd ADR stock quote for real-time trading data and today's change.
Takeda Pharmaceutical Co Ltd ADR Cash Flow Conversion Ratio Explained
Takeda Pharmaceutical Co Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Takeda Pharmaceutical Co Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Co Ltd ADR ranked by their cash flow conversion efficiency. Review TAK FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Target Corporation
NYSE:TGT
|
0.073x |
|
Vale S.A
MX:VALEN
|
0.062x |
|
Delta Air Lines Inc
NYSE:DAL
|
0.073x |
|
Elite Material Co Ltd
TW:2383
|
0.040x |
|
Diamondback Energy Inc
NASDAQ:FANG
|
0.055x |
|
Garmin Ltd
NYSE:GRMN
|
0.037x |
|
Société Générale Société anonyme
F:SGE1
|
N/A |
|
VOLVO B (FRIA) UNSP.ADR
F:VOL4
|
0.056x |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Co Ltd ADR (2001–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025. Also see balance sheet size of Takeda Pharmaceutical Co Ltd ADR for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.94 Trillion | $1.06 Trillion | 0.152x | +54.77% |
| 2024-03-31 | $7.27 Trillion | $716.34 Billion | 0.098x | -35.96% |
| 2023-03-31 | $6.35 Trillion | $977.16 Billion | 0.154x | -22.18% |
| 2022-03-31 | $5.68 Trillion | $1.12 Trillion | 0.198x | +1.20% |
| 2021-03-31 | $5.18 Trillion | $1.01 Trillion | 0.195x | +37.83% |
| 2020-03-31 | $4.73 Trillion | $669.75 Billion | 0.142x | +122.70% |
| 2019-03-31 | $5.16 Trillion | $328.48 Billion | 0.064x | -66.04% |
| 2018-03-31 | $2.02 Trillion | $377.85 Billion | 0.187x | +39.67% |
| 2017-03-31 | $1.95 Trillion | $261.36 Billion | 0.134x | +958.06% |
| 2016-03-31 | $2.01 Trillion | $25.49 Billion | 0.013x | -84.68% |
| 2015-03-31 | $2.21 Trillion | $182.52 Billion | 0.083x | +41.70% |
| 2014-03-31 | $2.54 Trillion | $148.34 Billion | 0.058x | -57.81% |
| 2013-03-31 | $2.22 Trillion | $307.71 Billion | 0.138x | -14.80% |
| 2012-03-31 | $2.07 Trillion | $336.57 Billion | 0.162x | +6.17% |
| 2011-03-31 | $2.14 Trillion | $326.94 Billion | 0.153x | -13.10% |
| 2010-03-31 | $2.16 Trillion | $381.17 Billion | 0.176x | +10.84% |
| 2009-03-31 | $2.05 Trillion | $326.27 Billion | 0.159x | +26.14% |
| 2008-03-31 | $2.32 Trillion | $292.50 Billion | 0.126x | +48.10% |
| 2007-03-31 | $2.46 Trillion | $209.28 Billion | 0.085x | -46.54% |
| 2006-03-31 | $2.35 Trillion | $373.57 Billion | 0.159x | +7.73% |
| 2005-03-31 | $2.00 Trillion | $295.54 Billion | 0.148x | -15.47% |
| 2004-03-31 | $1.78 Trillion | $311.12 Billion | 0.175x | +3.95% |
| 2003-03-31 | $1.57 Trillion | $263.45 Billion | 0.168x | +1.93% |
| 2002-03-31 | $1.46 Trillion | $240.59 Billion | 0.165x | -3.09% |
| 2001-03-31 | $1.25 Trillion | $212.66 Billion | 0.170x | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more